436 related articles for article (PubMed ID: 26238677)
1. Drug therapy for an overactive bladder.
Thiagamoorthy G; Cardozo L; Srikrishna S
Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
[No Abstract] [Full Text] [Related]
2. Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.
Sidaway P
Nat Rev Urol; 2015 Nov; 12(11):593. PubMed ID: 26345211
[No Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study.
Alcántara Montero A
Actas Urol Esp (Engl Ed); 2019; 43(1):51-52. PubMed ID: 30025617
[No Abstract] [Full Text] [Related]
4. Mirabegron (Myrbetriq) for overactive bladder.
Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
[No Abstract] [Full Text] [Related]
5. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
6. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis.
Yi W; Yang Y; Yang J
Medicine (Baltimore); 2021 Oct; 100(41):e27469. PubMed ID: 34731124
[TBL] [Abstract][Full Text] [Related]
9. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
10. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
11. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
14. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome.
Mandpe P; Prabhakar B; Shende P
Curr Drug Metab; 2020; 21(2):79-88. PubMed ID: 32334500
[TBL] [Abstract][Full Text] [Related]
15. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V
BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031
[TBL] [Abstract][Full Text] [Related]
16. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
17. N
Geoffrion R
J Obstet Gynaecol Can; 2017 Dec; 39(12):1230-1239. PubMed ID: 28986183
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.
Kallner HK; Christensson AA; Elmér C; Flam B; Altman D
Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():167-72. PubMed ID: 27318184
[TBL] [Abstract][Full Text] [Related]
19. [Idiopathic overactive bladder: What to do in case of anticholinergic failure?].
Boudy AS; Thubert T
Prog Urol; 2015 Jun; 25(8):497-8. PubMed ID: 25748787
[No Abstract] [Full Text] [Related]
20. Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Griebling TL
J Urol; 2015 Mar; 193(3):947. PubMed ID: 25765412
[No Abstract] [Full Text] [Related]
[Next] [New Search]
